Multiple endocrine neoplasia type 2 screening: Difference between revisions
Line 11: | Line 11: | ||
*The [[DNA]]-based testing of the c-[[RET proto-oncogene|''RET'' gene]] offers the opportunity for early identification of the c-''[[RET gene|RET]]'' germline [[mutation]]s, thus contributing to the reduction of morbidity and mortality of multiple endocrine neoplasia type 2 syndrome. In fact, the early recognition of the mutant [[gene]] carriers makes possible the prevention and cure of [[medullary thyroid cancer]], by performing a prophylactic [[thyroidectomy]] before the clinical expression of the [[tumor]]. | *The [[DNA]]-based testing of the c-[[RET proto-oncogene|''RET'' gene]] offers the opportunity for early identification of the c-''[[RET gene|RET]]'' germline [[mutation]]s, thus contributing to the reduction of morbidity and mortality of multiple endocrine neoplasia type 2 syndrome. In fact, the early recognition of the mutant [[gene]] carriers makes possible the prevention and cure of [[medullary thyroid cancer]], by performing a prophylactic [[thyroidectomy]] before the clinical expression of the [[tumor]]. | ||
*The [[DNA]]-based testing of the c-[[RET proto-oncogene|''RET'' gene]] test is also of importance to detect and thus, to reduce the risk of an unsuspected [[pheochromocytoma]].<ref name="Yip2003">{{cite journal|last1=Yip|first1=Linwah|title=Multiple Endocrine Neoplasia Type 2|journal=Archives of Surgery|volume=138|issue=4|year=2003|pages=409|issn=0004-0010|doi=10.1001/archsurg.138.4.409}}</ref> | *The [[DNA]]-based testing of the c-[[RET proto-oncogene|''RET'' gene]] test is also of importance to detect and thus, to reduce the risk of an unsuspected [[pheochromocytoma]].<ref name="Yip2003">{{cite journal|last1=Yip|first1=Linwah|title=Multiple Endocrine Neoplasia Type 2|journal=Archives of Surgery|volume=138|issue=4|year=2003|pages=409|issn=0004-0010|doi=10.1001/archsurg.138.4.409}}</ref> | ||
* Screening for multiple endocrine neoplasia type 2 include the following tests:<ref>Multiple endocrine neoplasia type2. Orphanet (30.10.2015). http://www.orpha.net/consor/cgi-bin/OC_Exp.php?Lng=GB&Expert=653 Accessed on October, 30, 2015</ref><ref name="MariniFalchetti2006">{{cite journal|last1=Marini|first1=Francesca|last2=Falchetti|first2=Alberto|last3=Del Monte|first3=Francesca|last4=Carbonell Sala|first4=Silvia|last5=Tognarini|first5=Isabella|last6=Luzi|first6=Ettore|last7=Brandi|first7=Maria|journal=Orphanet Journal of Rare Diseases|volume=1|issue=1|year=2006|pages=45|issn=17501172|doi=10.1186/1750-1172-1-45}}</ref> | * Screening for multiple endocrine neoplasia type 2 include the following tests:<ref>Multiple endocrine neoplasia type2. Orphanet (30.10.2015). http://www.orpha.net/consor/cgi-bin/OC_Exp.php?Lng=GB&Expert=653 Accessed on October, 30, 2015</ref><ref name="MariniFalchetti2006">{{cite journal|last1=Marini|first1=Francesca|last2=Falchetti|first2=Alberto|last3=Del Monte|first3=Francesca|last4=Carbonell Sala|first4=Silvia|last5=Tognarini|first5=Isabella|last6=Luzi|first6=Ettore|last7=Brandi|first7=Maria|journal=Orphanet Journal of Rare Diseases|volume=1|issue=1|year=2006|pages=45|issn=17501172|doi=10.1186/1750-1172-1-45}}</ref><ref>{{Cite journal | ||
| author = [[Friedhelm Raue]] & [[Karin Frank-Raue]] | |||
| title = Genotype-phenotype correlation in multiple endocrine neoplasia type 2 | |||
| journal = [[Clinics (Sao Paulo, Brazil)]] | |||
| volume = 67 Suppl 1 | |||
| pages = 69–75 | |||
| year = 2012 | |||
| month = | |||
| doi = 10.6061/clinics/2012(sup01)13 | |||
| pmid = 22584709 | |||
}}</ref> | |||
{| | {| |
Revision as of 13:52, 24 June 2019
Multiple endocrine neoplasia type 2 Microchapters |
Differentiating Multiple endocrine neoplasia type 2 from other Diseases |
---|
Diagnosis |
Treatment |
Multiple endocrine neoplasia type 2 screening On the Web |
American Roentgen Ray Society Images of Multiple endocrine neoplasia type 2 screening |
Directions to Hospitals Treating Multiple endocrine neoplasia type 2 |
Risk calculators and risk factors for Multiple endocrine neoplasia type 2 screening |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ammu Susheela, M.D. [2]
Overview
According to the American Society of Clinical Oncology, screening for multiple endocrine neoplasia type 2 by RET gene testing is recommended for children with increased risk of multiple endocrine neoplasia type 2.
Screening
- The DNA-based testing of the c-RET gene is recommended for children with increased risk of multiple endocrine neoplasia type 2.
- The DNA-based testing of the c-RET gene can be easily performed on a blood sample at any age.
- The DNA-based testing of the c-RET gene offers the opportunity for early identification of the c-RET germline mutations, thus contributing to the reduction of morbidity and mortality of multiple endocrine neoplasia type 2 syndrome. In fact, the early recognition of the mutant gene carriers makes possible the prevention and cure of medullary thyroid cancer, by performing a prophylactic thyroidectomy before the clinical expression of the tumor.
- The DNA-based testing of the c-RET gene test is also of importance to detect and thus, to reduce the risk of an unsuspected pheochromocytoma.[1]
- Screening for multiple endocrine neoplasia type 2 include the following tests:[2][3][4]
References
|